Medication info
Tradjenta Duo Tablet 2.5/1000 mg

Tradjenta Duo Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Boehringer Ingelheim Korea
Appearance
A bright pink, biconvex, oval film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTP pack x 6)]
Approval status
Active

MFDS item code 201208292 · Approved 2012.11.15 · Insurance code 653501410

Summary

Main use
Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients not achieving adequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients not achieving adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Importer
Boehringer Ingelheim Korea

Efficacy & effects

Improvement of blood glucose control in patients with type 2 diabetes

View approved original text

This medication helps patients with type 2 diabetes to control their blood sugar more effectively. It is particularly suitable for those who follow dietary and exercise therapy, enhancing blood glucose control through the combination of linagliptin and metformin, thus supporting health management. This medication significantly aids in the management of diabetes by improving blood glucose control.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients not achieving adequate glycemic control with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start with their existing doses of linagliptin and metformin. 4. Patients not achieving adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). 5. Patients not achieving adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication is a drug that helps control blood sugar. However, there are several important precautions you must know before taking this drug. First, one of the active ingredients, metformin, can cause a rare but serious side effect known as lactic acidosis. Lactic acidosis occurs when there is an excessive buildup of lactic acid in the body, which can be life-threatening if not treated, so you should seek immediate medical attention if symptoms appear. Second, this medication should not be administered to certain patients. For example, individuals allergic to this drug or its components, patients with type 1 diabetes, patients with severe kidney dysfunction, patients with acute heart issues or severe infections, as well as pregnant or breastfeeding women should not take this medication. Third, there is a risk of hypoglycemia with this medication, so blood sugar changes should be closely monitored, especially when taken with sulfonylureas or insulin. Additionally, patients with decreased kidney function should undergo regular kidney function tests, and those with significantly impaired kidney function should not take this medication. Fourth, rare skin conditions such as acute pancreatitis or bullous pemphigoid may occur while taking this medication, so if you experience severe abdominal pain or develop blisters on the skin, you should consult with a healthcare professional immediately. Fifth, metformin can lower vitamin B12 levels, so it is necessary to regularly check for vitamin B12 deficiency if taking this drug over the long term. Sixth, this medication may interact with other drugs, so you must inform your doctor or pharmacist of any medications you are currently taking. Special caution is needed when taken with drugs that may affect kidney function, certain antibiotics, diuretics, or antihypertensives. Seventh, women who are pregnant or planning to become pregnant are advised not to take this medication, and it should be avoided during breastfeeding as well. Eighth, this medication is not recommended for children or those under 10 years of age, as its safety and efficacy have not been established in this population. Ninth, there may be a risk of decreased kidney function in the elderly, so appropriate dose adjustments and regular kidney function tests are necessary. Finally, in case of overdose, serious side effects such as gastrointestinal disturbances or lactic acidosis may occur, so you should strictly adhere to the dosage guidelines, and if an overdose is suspected, seek immediate medical attention. Store this medication out of reach of children and avoid humidity when storing it. Also, it is safer to avoid transferring it to other containers. If you follow all these precautions carefully, this medication can help control blood sugar levels. If you experience any abnormal symptoms while taking it, consult with a healthcare professional immediately.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of vitamin B12
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 125 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • anxiety
  • depression
  • bruise
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • thyromegaly
  • anemia
  • dizziness
  • drowsiness
  • itching
  • insomnia
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • gingivitis
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • confusion state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is important to store it at room temperature between 1 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A bright pink, biconvex, oval film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTP pack x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.